🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Biocon Limited BIOCON NIFTY_MIDNSEPHARMA

Healthcare · Biotechnology · India
https://www.biocon.com

Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics, Biosimilars, and Research segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, anti-fungal, anti-cancer, immunosuppressants, and specialty molecules; and biosimilars products consisting of pegfilgrastim, trastuzumab, bevacizumab, adalimumab, etanercept, ustekinumab, glargine, aspart, insulins, and aflibercept. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods, and agrochemical companies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services, and other research and development in the fields of pharmaceuticals, drug discovery, biotechnology pharmaceuticals, and medicinal sciences, etc.; clinical research; and business support and development, and marketing services. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.

READ MORE ›
₹428.65
+27.90% 1Y

Market & Price

Market Cap
₹69,412.64 Cr
Current Price
₹428.65
High / Low (52W)
₹436.15 / ₹329.61
Beta
0.23

Valuation

Stock P/E
151.47
Industry PE
37.60
Forward P/E
36.12
PEG Ratio
-
Book Value
₹213.54
Price to Book
2.01
P/S
4.10
EV/EBITDA
23.86
Dividend Yield
0.12%

Profitability & Returns

ROCE
2.90%
ROE
1.15%
ROA
1.53%
Profit Margin
2.28%
Op Margin
11.22%
EPS (Latest Qtr)
₹0.79
EPS (TTM)
₹2.83

Balance Sheet & Liquidity

Debt/Equity
0.42
Quick Ratio
0.70
Current Ratio
1.22
Debt
₹15,434.10 Cr
Total Assets
₹63,650.60 Cr
Current Assets
₹17,179.80 Cr
Working Capital
₹3,110.60 Cr

Ownership

Promoter Holding
54.07%
Chg in Prom Hold
-
FII / Inst Holding
26.12%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹82,453.10 Cr
Total Revenue (TTM)
₹16,927.00 Cr
EBITDA
₹3,455.30 Cr
Free Cash Flow
₹-46.61 Cr
Operating Cash Flow
₹1,994.00 Cr
Shares Outstanding
₹161.93 Cr
Gross Margin
66.38%
Payout Ratio
17.73%

Growth (CAGR)

Revenue 5Y
15.35%
Profit 5Y
-5.90%
Revenue (YoY)
2.30%
Earnings (YoY)
-72.50%

PROS

  • Compounding revenue at 15.3% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 151.5.
  • Earnings shrank at -5.9% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 BIOCON Biocon Limited NIFTY_MIDNSEPHARMA 428.65 151.47 ₹69,412.64 Cr 0.12% 2.90% 1.15% 15.35% -5.90%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,799.20 37.59 ₹4.32 L Cr 0.92% 17.94% 14.72% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 6,667.00 68.97 ₹1.77 L Cr 0.45% 18.96% 16.19% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,410.80 68.96 ₹1.49 L Cr 0.86% 9.06% 16.98% 13.27% 20.21%
5 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,401.00 29.16 ₹1.13 L Cr 0.93% 14.88% 11.74% 7.23% 11.45%
6 DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA 1,303.50 25.90 ₹1.09 L Cr 0.61% 14.00% 11.83% 10.96% -2.35%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,077.70 21.51 ₹1.08 L Cr 0.09% 19.24% 18.32% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,267.70 19.49 ₹1.04 L Cr 0.53% 28.42% 26.91% 19.10% 131.46%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,375.60 51.29 ₹98,090.71 Cr 0.08% 13.78% 12.45% 17.73% 14.28%
⚙Ad space

Quarterly Results

Figures in INR.

Metric Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 4,358.10 Cr3,910.10 Cr4,262.50 Cr4,173.00 Cr4,484.30 Cr
Cost of Revenue 1,472.90 Cr1,405.10 Cr1,547.00 Cr1,339.30 Cr1,399.30 Cr
Gross Profit 2,885.20 Cr2,505.00 Cr2,715.50 Cr2,833.70 Cr3,085.00 Cr
Operating Expenses 2,243.30 Cr2,211.10 Cr2,353.10 Cr2,515.50 Cr2,578.10 Cr
Operating Income 641.90 Cr293.90 Cr362.40 Cr318.20 Cr506.90 Cr
EBITDA 1,135.50 Cr828.60 Cr916.50 Cr657.40 Cr992.40 Cr
Interest Expense 212.40 Cr276.70 Cr272.20 Cr209.90 Cr231.50 Cr
Pretax Income 486.80 Cr96.90 Cr171.30 Cr-67.80 Cr247.50 Cr
Tax Provision 27.40 Cr7.70 Cr38.50 Cr-16.00 Cr48.90 Cr
Net Income 344.50 Cr31.40 Cr84.50 Cr143.80 Cr125.90 Cr
Diluted EPS 2.870.260.651.070.79

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -10,934.10 Cr14,195.80 Cr15,052.20 Cr16,779.90 Cr
Cost of Revenue -3,666.80 Cr4,906.60 Cr5,197.50 Cr5,690.70 Cr
Gross Profit -7,267.30 Cr9,289.20 Cr9,854.70 Cr11,089.20 Cr
Operating Expenses -5,640.20 Cr7,854.70 Cr8,375.40 Cr9,590.60 Cr
Operating Income -1,627.10 Cr1,434.50 Cr1,479.30 Cr1,498.60 Cr
EBITDA -2,429.20 Cr4,068.40 Cr4,471.00 Cr3,394.90 Cr
Interest Expense -419.00 Cr974.40 Cr897.40 Cr990.30 Cr
Pretax Income -897.10 Cr1,525.20 Cr1,886.60 Cr447.90 Cr
Tax Provision -254.10 Cr227.40 Cr457.20 Cr79.10 Cr
Net Income -462.70 Cr1,022.50 Cr1,013.30 Cr385.60 Cr
Diluted EPS -3.878.548.462.82

Compounded Sales Growth

5 Years:15.35%
1 Year:2.30%

Compounded Profit Growth

5 Years:-5.90%
1 Year:-72.50%

Stock Price Performance

1 Year:+27.90%
6 Months:+8.45%
3 Months:+10.56%
1 Month:+18.33%

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -52,042.80 Cr56,070.70 Cr58,797.30 Cr63,650.60 Cr
Current Assets -12,334.00 Cr15,179.20 Cr16,286.20 Cr17,179.80 Cr
Cash & Equivalents -1,323.20 Cr1,233.40 Cr3,226.70 Cr2,416.50 Cr
Inventory -4,243.70 Cr4,943.90 Cr4,931.10 Cr6,085.70 Cr
Receivables -3,573.20 Cr6,230.60 Cr5,487.90 Cr5,986.80 Cr
Total Liabilities -29,554.00 Cr30,795.90 Cr31,084.80 Cr27,029.10 Cr
Current Liabilities -8,510.70 Cr15,358.80 Cr14,333.80 Cr14,069.20 Cr
Long Term Debt -15,290.50 Cr12,932.40 Cr12,405.40 Cr10,746.30 Cr
Total Debt -18,018.80 Cr16,276.70 Cr18,362.00 Cr15,434.10 Cr
Total Equity -17,866.90 Cr19,783.70 Cr21,644.00 Cr34,031.80 Cr
Shares Outstanding -120.06 Cr120.06 Cr120.06 Cr161.93 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -1,852.50 Cr2,953.90 Cr4,061.20 Cr1,994.00 Cr
Investing Cash Flow --14,281.80 Cr-1,004.50 Cr-234.10 Cr-2,082.10 Cr
Financing Cash Flow -13,048.70 Cr-2,332.70 Cr-1,854.00 Cr-923.60 Cr
Capital Expenditure --1,726.30 Cr-1,931.60 Cr-2,343.30 Cr-1,911.70 Cr
Free Cash Flow -126.20 Cr1,022.30 Cr1,717.90 Cr82.30 Cr
Net Change in Cash -619.40 Cr-383.30 Cr1,973.10 Cr-1,011.70 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -66.5%65.4%65.5%66.1%
Operating Margin % -14.9%10.1%9.8%8.9%
Net Margin % -4.2%7.2%6.7%2.3%
ROE % -2.6%5.2%4.7%1.1%
ROCE % -3.7%3.5%3.3%3.0%

Shareholding Pattern

Insiders
54.07%
Institutions
26.12%
Public Float
56.87%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for BIOCON

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space